RxDoctor Payments Data

Tami Hall

Family · McDonough, GANPI 1407147754

Payments from drug & device makers

$406in general payments, 2019–2025

Across 17 payments — averaging $23.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$205
  • Otsuka America Pharmaceutical, Inc.$40
  • Baxter Healthcare$38
  • AbbVie$35
  • GSK$32
  • Sanofi-aventis U.S. LLC$24
  • plus $31 from 2 others

What the payments were for

  • Consulting fees$154%
  • Food & beverage$39196%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$406 in reported general payments places this provider in the 50th percentile of 6,258 family providers in Georgia.

See all family providers in Georgia

Medicare billing

Part B allowed, 2024
$62,874
Medicare patients
186
Services billed
2,562

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide41$64,191
JanuviaSitagliptin Phosphate29$43,934
MounjaroTirzepatide35$37,365
RybelsusSemaglutide19$36,067
JardianceEmpagliflozin23$31,832
TrulicityDulaglutide14$26,258
FarxigaDapagliflozin Propanediol15$16,853
Tresiba Flextouch U-200Insulin Degludec11$10,049
Lantus SolostarInsulin Glargine,hum.Rec.Anlog19$2,433
Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide23$1,529
Amlodipine Besylate222$1,526
Albuterol Sulfate HfaAlbuterol Sulfate37$1,339
Omeprazole103$1,301
Rosuvastatin Calcium89$1,024
Pravastatin Sodium51$988

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$205$100,25760 claims
AstraZenecaFarxiga$13$16,85315 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 6,258 family providers in Georgia.

Other family in McDonough

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →